Form 8-K - Current report:
SEC Accession No. 0001213900-24-007150
Filing Date
2024-01-29
Accepted
2024-01-29 06:31:15
Documents
16
Period of Report
2024-01-29
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea192239-8k_gamida.htm   iXBRL 8-K 36918
2 PRESS RELEASE, DATED JANUARY 29, 2024 ea192239ex99-1_gamida.htm EX-99.1 6831
6 GRAPHIC ex99-1_001.jpg GRAPHIC 2540
  Complete submission text file 0001213900-24-007150.txt   223433

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE gmda-20240129.xsd EX-101.SCH 3024
4 XBRL LABEL FILE gmda-20240129_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE gmda-20240129_pre.xml EX-101.PRE 22365
17 EXTRACTED XBRL INSTANCE DOCUMENT ea192239-8k_gamida_htm.xml XML 3701
Mailing Address 5 NAHUM HAFZADI STREET JERUSALEM L3 95484
Business Address 5 NAHUM HAFZADI STREET JERUSALEM L3 95484 97226595666
Gamida Cell Ltd. (Filer) CIK: 0001600847 (see all company filings)

EIN.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38716 | Film No.: 24570013
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)